James N. Ingle

Active 1981–2025

139
Papers
47,484
Citations
94
h-index
137
i10-index

Citations

Citations per year for James N. Ingle1974: 2 citations1980: 1 citations1981: 2 citations1982: 1 citations1983: 1 citations1984: 3 citations1986: 2 citations1987: 2 citations1988: 7 citations1989: 3 citations1990: 4 citations1991: 4 citations1992: 7 citations1993: 8 citations1994: 3 citations1995: 6 citations1996: 7 citations1997: 9 citations1998: 26 citations1999: 33 citations2000: 53 citations2001: 68 citations2002: 77 citations2003: 147 citations2004: 176 citations2005: 226 citations2006: 311 citations2007: 377 citations2008: 421 citations2009: 410 citations2010: 425 citations2011: 412 citations2012: 370 citations2013: 397 citations2014: 340 citations2015: 371 citations2016: 397 citations2017: 350 citations2018: 325 citations2019: 1,117 citations2020: 1,184 citations2021: 984 citations2022: 782 citations2023: 541 citations2024: 867 citations2025: 377 citations2026: 12 citations1975–1979: no citations, so these years are not shown1985: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,307 citing papers, 27.5% of this breakdownChina: 1,252 citing papers, 8% of this breakdownUnited Kingdom: 1,000 citing papers, 6.4% of this breakdownItaly: 903 citing papers, 5.8% of this breakdownGermany: 762 citing papers, 4.9% of this breakdownCanada: 665 citing papers, 4.2% of this breakdownFrance: 515 citing papers, 3.3% of this breakdownAustralia: 431 citing papers, 2.7% of this breakdownSwitzerland: 420 citing papers, 2.7% of this breakdownSpain: 391 citing papers, 2.5% of this breakdownBelgium: 365 citing papers, 2.3% of this breakdownNetherlands: 365 citing papers, 2.3% of this breakdown
0%27.5%Other 27.4%

Fields

  • Medicine47.5%
  • Biochemistry, Genetics and Molecular Biology43.1%
  • Pharmacology, Toxicology and Pharmaceutics2.1%
  • Immunology and Microbiology2%
  • Computer Science1.7%
  • Engineering0.6%
  • Other3%

Topics

  • Breast Cancer Treatment Studies10.8%
  • HER2/EGFR in Cancer Research6.3%
  • Estrogen and related hormone effects4%
  • Advanced Breast Cancer Therapies3.4%
  • Breast Lesions and Carcinomas3.4%
  • Cancer Cells and Metastasis3.1%
  • Other69%

Coauthors

All papers

Open in search
  1. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Clifford A. Hudis, James N. Ingle, Jacek Jassem, Zefei Jiang, Per Karlsson, Sibylle Loibl, Monica Morrow, Moïse Namer, C. Kent Osborne, Ann H. Partridge, Frédérique Penault‐Llorca, Charles M. Perou, Martine Piccart, Kathleen I. Pritchard, Emiel J. Rutgers, Felix Sedlmayer, Semiglazov Vf, Zhi‐Ming Shao, Ian Smith, Beat Thürlimann, Masakazu Toi, Andrew Tutt, Michael Untch, Giuseppe Viale, Toru Watanabe, Nicholas Wilcken, Eric P. Winer, William C. Wood - Annals of Oncology 2013 cited by 3,715

  2. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mitch Dowsett, Frances Duane, Vaughan Evans, Marianne Ewertz, Bernard Fisher, John Forbes, Leslie G. Ford, J.-C. Gazet, Richard D. Gelber, Lucy Gettins, Luca Gianni, Michael Gnant, Jon Godwin, Aron Goldhirsch, Pamela J. Goodwin, Richard Gray, Daniel F. Hayes, Catherine Hill, James N. Ingle, Reshma Jagsi, R. Jakesz, Sam James, Wolfgang Janni, Hui Liu, Zulian Liu, Caroline Lohrisch, Sibylle Loibl, Liz MacKinnon, Andreas Makris, Eleftherios P. Mamounas, Gurdeep Mannu, Miguel Martín, S. Mathoulin, L. Mauriac, Paul McGale, Theresa McHugh, Philip Morris, Hirofumi Mukai, Larry Norton, Yasuo Ohashi, Ivo A. Olivotto, Soon Young Paik, Hongchao Pan, Richárd Pető, Martine Piccart, Lori J. Pierce, Philip Poortmans, Trevor J. Powles, K.I. Pritchard, Joseph Ragaz, Vinod Raina, Peter M. Ravdin, Simon Read, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Suzy Scholl, Dennis J. Slamon, Lidija Sölkner, Joseph A. Sparano, Seth M. Steinberg, Rosemary Sutcliffe, Sandra M. Swain, Carolyn Taylor, Andrew Tutt, Pinuccia Valagussa, Cornelis J.�H. van de Velde, Jos A. van der Hage, Giuseppe Viale, Gϋnter von Minckwitz and 10 more - The Lancet Oncology 2017 cited by 1,133

  3. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2005 cited by 5,353

  4. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Clifford A. Hudis, James N. Ingle, Jacek Jassem, Zefei Jiang, Per Karlsson, Monica Morrow, Roberto Orecchia, C. Kent Osborne, Ann H. Partridge, Lorena de la Peña, Martine Piccart, Kathleen I. Pritchard, Emiel J. Rutgers, Felix Sedlmayer, Semiglazov Vf, Zhi‐Ming Shao, Ian Smith, Beat Thürlimann, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Gϋnter von Minckwitz, Toru Watanabe, Timothy J. Whelan, Eric P. Winer, Binghe Xu - Annals of Oncology 2015 cited by 1,837

  5. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Barbara Ruepp, Angelo Di Leo, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan - New England Journal of Medicine 2018 cited by 673

  6. Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 cited by 645

  7. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

    Authors: , , , , , , , , , , , , , , , , , , , , , - 2003 cited by 442

  8. Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jon Godwin, Sam James, Amanda Kerr, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Mariko Nakahara, Simon Read, Hannah Taylor, John Ferguson, H Scheurlen, Stefano Zurrida, Viviana Galimberti, James N. Ingle, Pinuccia Valagussa, Umberto Veronesi, Stewart Anderson, Gong Tang, Bernard Fisher, Sophie D. Fosså, Kristin V. Reinertsen, Herman Høst, Hyman B. Muss, Kaija Holli, Kathy S. Albain, R. Arriagada, John M.S. Bartlett, Elizabeth Bergsten-Nordström, Judith M. Bliss, Étienne Brain, Lisa A. Carey, Robert E. Coleman, Jack Cuzick, Nancy E. Davidson, Lucia Del Mastro, Angelo Di Leo, James J. Dignam, Mitch Dowsett, Bent Ejlertsen, Prue Francis, José Á. García-Sáenz, Rich Gelber, Michael Gnant, Matthew P. Goetz, Pam Goodwin, Pat Halpin-Murphy, Dan Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P. Mamounas, Miguel Martín, Stuart McIntosh, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Martine Piccart, Lori J. Pierce, Vinod Raina, Daniel Rea, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Roberto Salgado, Dennis J. Slamon, Tanja Španić and 14 more - The Lancet 2023 cited by 151

  9. Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2013 cited by 740

  10. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

    Authors: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 cited by 648

  11. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2003 cited by 1,564

  12. A comprehensive analysis of breast cancer microbiota and host gene expression

    Authors: , , , , , , , , , , , , , , , , , - PLoS ONE 2017 cited by 179

  13. Exemestane for Breast-Cancer Prevention in Postmenopausal Women

    Authors: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2011 cited by 961

  14. Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 cited by 727

  15. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2009 cited by 1,405

  16. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

    Authors: , , , , , , , , , , , , , , - Clinical Pharmacology & Therapeutics 2018 cited by 324

  17. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 58

  18. Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2023 cited by 52

  19. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells

    Authors: , , , , , - Oncogene 2013 cited by 293

  20. Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response

    Authors: , , , , , , , , , , , , , , , , , , , - NAR Cancer 2022 cited by 43

  21. Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance

    Authors: , , , , , , , , , , , , , , , , , , , , - Oncogene 2021 cited by 102

  22. Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2023 cited by 44

  23. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307

    Authors: , , , , , , , , , , , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2019 cited by 78

  24. Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)

    Authors: , , , , , , - Journal of Clinical Oncology 2003 cited by 707